Menu

A recent study from the group of Prof. Miron of the College of Dental Medicine, at the Nova Southeastern University, FL (USA), confirmed the following properties of maxresorb®: Ideal rough surface Great potential to absorb/release growth factors, such as rhBMP2 and rhBMP9 Significant stimulation of osteoblast differentiation These are all crucial properties for bony regeneration! Published in: Clin Oral Investig. 2016 Oct 22. [Epub ahead of print]. Recombinant human bone morphogenetic protein (rhBMP)9 induces osteoblast differentiation when combined with demineralized freeze-dried bone allografts (DFDBAs) or biphasic calcium phosphate (BCP). Fujioka-Kobayashi M, Schaller B, Zhang Y, Kandalam U, Hernandez M, Miron RJ. More information on maxresorb® at https://botiss-dental.com/products/maxresorb/ The study is available here: https://www.ncbi.nlm.nih.gov/pubmed/27771827...

On November the 25th, the 2nd mucoderm® expert meeting has taken place in Hamburg, Germany. The aim of the meeting was to review the currently available clinical/scientific data, in order to set up further guidelines for the use of the porcine matrix in established indications and explore new fields of indications/limitations of mucoderm®. To this end, botiss and Straumann invited seven experienced clinicians with different specializations. Prof. Dr. Adrian Kasaj (University of Mainz, Germany), Dr. Raluca Cosgarea (University Cluij-Napocca, Romania and Marburg, Germany), and Dr. Attila Horváth (University of Budapest, Hungary) presented their results obtained with mucoderm® in combination with the modified coronally advanced tunnel or the Zucchelli technique for the treatment of gingival recessions, showing predictable results for Miller class I and II recessions. Dr. Dominiki Chatzopoulou (University of London, UK) pointed out the potential benefits of combining mucoderm® with Emdogain®, particularly for compromised patients and smokers. Dr. Alessandro Rossi (University...